Navigation Links
BioMS Medical's phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
Date:4/14/2009

Toronto Stock Exchange Symbol: MS

EDMONTON, April 14 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the independent Data Safety Monitoring Board (DSMB) for the Company's U.S. pivotal phase III MAESTRO-03 trial of dirucotide in patients with secondary progressive MS has completed a safety analysis and recommended that the trial continue as per the protocol.

This was the fourth of several regularly scheduled reviews by the DSMB that will occur over the duration of the trial. The purpose of the DSMB is to provide objective, independent safety monitoring of the trial.

    About MAESTRO-03
    ----------------

The MAESTRO-03 U.S. pivotal phase III clinical trial is a randomized, double-blind study that has completed recruitment of approximately 510 patients at 67 clinical sites who will be administered either dirucotide or placebo intravenously every six months for a period of two years. The primary clinical endpoint for the trial is defined as a statistically and clinically significant increase in the time to progression of the disease as measured by the Expanded Disability Status Scale (EDSS), in patients with HLA-DR2 and/or HLA-DR4 immune response genes (up to 70% of all MS patients are HLA-DR2 and/or HLA-DR4 positive).

    About BioMS Medical Corp.
    -------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, dirucotide, is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for Secondary Progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Compan
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMS Medical Announces 2008 Year End Results
2. BioMS Medical warrant extension
3. BioMS Medical to present at BIO CEO and Investor Conference
4. BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis
5. BioMS Medical recognized at Scrip Awards 2008
6. BioMS Medical Announces Third Quarter 2008 Results
7. BioMS Medical to present at Rodman and Renshaw Annual Healthcare Conference
8. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
9. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
10. BioMS Medical announces receipt of milestone payment from Eli Lilly and Company
11. BioMS Medical to present at Sachs Associates Biotech in Europe Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... device," Nobel laureate Herbert Kroemer famously observed, referring ... the junctures where layers of different materials meet. ... between layers of metal oxides are becoming increasingly ... spintronics, high-temperature superconductors, ferroelectrics and multiferroics. Realizing the ...
(Date:1/15/2014)... 15, 2014   Niagara Thermal Products is proud ... BioBlower Technologies LLC ("B3") as the critical thermal component ... from the Army Corps of Engineers.  B3 has developed ... biological contaminants and destroys VOCs and other chemical pollutants, ...
(Date:1/15/2014)... and SAN JOSE, California , January ... company developing antibody-drug conjugates for cancer, today announced the appointment ... Directors. Dr Reynolds has over 20 years, development experience gained ... at Seattle Genetics. "I am delighted to welcome ...
(Date:1/15/2014)... 2014 A study has been launched to ... 1 track could help to tackle the problem of obesity. ... (a GP surgery based in Stowmarket) and academics at University ... Telemetry technology, which is inspired by equipment used to ...
Breaking Biology Technology:A deeper look at interfaces 2Niagara Thermal Products LLC Selected as Critical Supplier for Buffalo BioBlower Air Purification Systems 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4
... VIEW, Calif., Nov. 7, 2011 VIVUS, Inc. (NASDAQ: ... and commercialization of novel therapeutic products, today reported its financial ... 30, 2011. Third Quarter ResultsFor the ... loss of $8.6 million, or $0.10 net loss per share, ...
... November 7, 2011 Note: numbers in square ... Boulter is available for interview. Investment fund manager ... today won a court battle with 3M over the multi-national ... The High Court in London found 3M was ...
... HANOVER, N.J., Nov. 7, 2011 Novartis announced today ... with active systemic juvenile idiopathic arthritis (SJIA) were able ... described as steroids) within 28 weeks of commencing treatment ... of the study, which met both primary endpoints, will ...
Cached Biology Technology:VIVUS Reports Third Quarter and First Nine Months 2011 Financial Results 2VIVUS Reports Third Quarter and First Nine Months 2011 Financial Results 3VIVUS Reports Third Quarter and First Nine Months 2011 Financial Results 4VIVUS Reports Third Quarter and First Nine Months 2011 Financial Results 5VIVUS Reports Third Quarter and First Nine Months 2011 Financial Results 6VIVUS Reports Third Quarter and First Nine Months 2011 Financial Results 7VIVUS Reports Third Quarter and First Nine Months 2011 Financial Results 8VIVUS Reports Third Quarter and First Nine Months 2011 Financial Results 93M Forced to Pay for Breach of Obligations Over MRSA - High Court 23M Forced to Pay for Breach of Obligations Over MRSA - High Court 33M Forced to Pay for Breach of Obligations Over MRSA - High Court 4Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis 2Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis 3Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis 4Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis 5Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis 6Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis 7
(Date:4/17/2014)... MANHATTAN, KAN. A Kansas State University engineer ... security and remotely detects improvised explosive devices. The ... , William Dunn, the Steven M. and Kay ... of mechanical and nuclear engineering, and his research ... explosives hidden underground or in car trunks. The ...
(Date:4/17/2014)... Calif. One day about eight years ago, ... California, Riverside, and her father were on a field trip ... upon an orchid they had never seen before. , Unable ... on orchids. The orchid turned out to be an ... Lophiaris silverarum . , "Lophiaris" is the genus name, ...
(Date:4/17/2014)... is available in German . ... the protection money demanded of him, he can expect his ... however, as fear of the consequences is enough to make ... parasitic birds, which lay their eggs in other birds, nests. ... brood parasites take their revenge by destroying the entire nest. ...
Breaking Biology News(10 mins):Patented research remotely detects nitrogen-rich explosives 2Orchid named after UC Riverside researcher 2Orchid named after UC Riverside researcher 3Fear of the cuckoo mafia 2Fear of the cuckoo mafia 3
... 2012 Chiltern International Limited (Chiltern), a global contract ... James Gunter have joined Chiltern, bringing their expertise in ... strengthen our Global Clinical Development services. ... Cedric Burg has been appointed to the position of ...
... pests by using ultrasonic frequencies are available and marketed ... been demonstrated as being effective in repelling insect pests ... of evidence for the efficacy of such devices, they ... bugs are readily available. However, according to a ...
... reprogramming a 7-year-old girl,s own immune cells to attack ... has achieved a complete response in his patient, who ... The innovative experimental therapy used bioengineered T cells, custom-designed ... leukemia cells. After the treatment, the child,s doctors found ...
Cached Biology News:Chiltern Welcomes Cedric Burg And James Gunter 2Engineered immune cells produce complete response in child with an aggressive pediatric leukemia 2Engineered immune cells produce complete response in child with an aggressive pediatric leukemia 3
... cultured in DMEM with 4 mM L-glutamine medium ... In order to keep the antigens in ... The cells are arrayed on a 12-well ... surface specifically treated to enhance cellular attachment and ...
... cultured in DMEM and harvested at the log ... the antigens in their native forms, cells were ... on a 12-well (5 mm) adhesive coated slide, ... cellular attachment and to minimize background staining. ...
... P815 cells were cultured in DMEM and harvested ... order to keep the antigens in their native ... cells are arrayed on a 12-well (5 mm) ... treated to enhance cellular attachment and to minimize ...
...
Biology Products: